| scholarly article | Q13442814 |
| P50 | author | Richard A. Larson | Q41899936 |
| Brian Druker | Q373427 | ||
| P2093 | author name string | Insa Gathmann | |
| Francois Guilhot | |||
| Yanfeng Wang | |||
| Stephen G O'Brien | |||
| Tillmann Krahnke | |||
| Gilles J Riviere | |||
| IRIS (International Randomized Interferon vs STI571) Study Group | |||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| imatinib | Q177094 | ||
| pharmacokinetics | Q323936 | ||
| chronic myeloid leukemia | Q729735 | ||
| P304 | page(s) | 4022-4028 | |
| P577 | publication date | 2008-02-06 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study | |
| P478 | volume | 111 |
| Q33424413 | A Single-Arm Phase 1b Study of Everolimus and Sunitinib in Patients With Advanced Renal Cell Carcinoma |
| Q37610139 | A benefit-risk assessment of imatinib in chronic myeloid leukaemia and gastrointestinal stromal tumours |
| Q34316796 | A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate |
| Q84449632 | A method for quantitative analysis of an anticancer drug in human plasma with CE-ESI-TOF-MS |
| Q34065271 | A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug |
| Q45228150 | A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer |
| Q90320606 | A phosphoproteomic signature in endothelial cells predicts vascular toxicity of tyrosine kinase inhibitors used in CML |
| Q48324100 | A quantitative method for the determination of bosutinib in human plasma using high-performance liquid chromatography and ultraviolet detection. |
| Q33427392 | A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients. |
| Q37652283 | ABCB1 haplotypes are associated with P-gp activity and affect a major molecular response in chronic myeloid leukemia patients treated with a standard dose of imatinib. |
| Q37140624 | ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitro |
| Q37396085 | Acute dasatinib exposure commits Bcr-Abl-dependent cells to apoptosis |
| Q43102333 | Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. |
| Q83978305 | Adherence to the standard dose of imatinib, rather than dose adjustment based on its plasma concentration, is critical to achieve a deep molecular response in patients with chronic myeloid leukemia |
| Q37057014 | Adherence to treatment with imatinib in chronic myeloid leukemia: a study of the first decade of responses obtained at a Brazilian hospital |
| Q46047555 | Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel |
| Q37657488 | Advances in treatment of chronic myelogenous leukemia--new treatment options with tyrosine kinase inhibitors |
| Q39202778 | Allogeneic stem cell transplantation for patients with chronic myeloid leukemia: risk stratified approach with a long-term follow-up. |
| Q41568738 | An Automated Homogeneous Immunoassay for Quantitating Imatinib Concentrations in Plasma. |
| Q36083906 | An LC-MS/MS method for rapid and sensitive high-throughput simultaneous determination of various protein kinase inhibitors in human plasma. |
| Q34411016 | As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. |
| Q90682089 | Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology |
| Q36579071 | Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy |
| Q83145640 | Association of SLCO1B3 polymorphism with intracellular accumulation of imatinib in leukocytes in patients with chronic myeloid leukemia |
| Q34245458 | Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis |
| Q41357273 | BCR-ABL kinase is dead; long live the CML stem cell |
| Q50600192 | BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. |
| Q26824660 | Biomarkers for determining the prognosis in chronic myelogenous leukemia |
| Q36229161 | CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients |
| Q43200942 | CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity |
| Q37281684 | Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers |
| Q48278939 | Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients? |
| Q54578490 | Capillary electrophoresis method for plasmatic determination of imatinib mesylate in chronic myeloid leukemia patients. |
| Q83204461 | Changes in imatinib plasma trough level during long-term treatment of patients with advanced gastrointestinal stromal tumors: correlation between changes in covariates and imatinib exposure |
| Q34052174 | Characterization of the Src/Abl hybrid kinase SmTK6 of Schistosoma mansoni |
| Q57157512 | Chemotherapy for Fighting Schistosomiasis: Past, Present and Future |
| Q37738569 | Chronic myelogenous leukemia stem cells: What's new? |
| Q45358123 | Chronic myeloid leukaemia and human immunodeficiency virus (HIV) infection. |
| Q37579283 | Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the best therapy? |
| Q37163550 | Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet |
| Q36006408 | Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib |
| Q55070999 | Clinical characteristics and therapeutic outcomes of elderly patients with chronic myeloid leukemia: A retrospective multicenter study. |
| Q33952848 | Clinical characteristics and treatment outcome of pediatric patients with chronic myeloid leukemia |
| Q26775822 | Clinical development of nintedanib for advanced non-small-cell lung cancer |
| Q37630453 | Clinical efficacy and safety of imatinib in the management of Ph(+) chronic myeloid or acute lymphoblastic leukemia in Chinese patients |
| Q33926222 | Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia |
| Q37504935 | Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour. |
| Q37489609 | Clinical profile of dasatinib in Asian and non-Asian patients with chronic myeloid leukemia |
| Q39116591 | Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. |
| Q36566250 | Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients |
| Q36374813 | Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders |
| Q42117946 | Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy |
| Q35946876 | Contribution of tumoral and host solute carriers to clinical drug response |
| Q42845531 | Correlation between imatinib pharmacokinetics and clinical response in Japanese patients with chronic-phase chronic myeloid leukemia. |
| Q37731289 | Correlations between imatinib pharmacokinetics, pharmacodynamics, adherence, and clinical response in advanced metastatic gastrointestinal stromal tumor (GIST): an emerging role for drug blood level testing? |
| Q91952960 | Correlations between imatinib plasma trough concentration and adverse reactions in Chinese patients with gastrointestinal stromal tumors |
| Q92205556 | Cost effectiveness of therapeutic drug monitoring for imatinib administration in chronic myeloid leukemia |
| Q46510723 | Current diagnostic requirements in chronic myeloid leukemia |
| Q38787015 | Current trends in molecular diagnostics of chronic myeloid leukemia |
| Q54263364 | Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations. |
| Q52631989 | Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. |
| Q41501849 | Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance. |
| Q46179041 | Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform |
| Q36933601 | Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study |
| Q45160680 | Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat. |
| Q38899401 | Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy? |
| Q55002373 | Do polymorphisms in MDR1 and CYP3A5 genes influence the risk of cytogenetic relapse in patients with chronic myeloid leukemia on imatinib therapy? |
| Q37789148 | Do we have to kill the last CML cell? |
| Q35035596 | Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer |
| Q54596369 | Dose escalation of imatinib in chronic-phase chronic myeloid leukemia patients: is it still reasonable? |
| Q46123265 | Drug monitoring of imatinib levels in patients undergoing therapy for chronic myeloid leukaemia: comparing plasma levels of responders and non-responders |
| Q38791448 | Dynamics of Expression of Drug Transporters: Methods for Appraisal |
| Q89143938 | Early BCR-ABL1 decline in imatinib-treated patients with chronic myeloid leukemia: results from a multicenter study of the Chinese CML alliance |
| Q34580581 | Effects of imatinib mesylate on the pharmacokinetics of paracetamol (acetaminophen) in Korean patients with chronic myelogenous leukaemia |
| Q33886167 | Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia |
| Q37150014 | Efficacy of imatinib mesylate-based front-line therapy in pediatric chronic myelogenous leukemia |
| Q34339623 | Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumors |
| Q37249366 | Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer |
| Q33878471 | Environmental and genetic factors affecting transport of imatinib by OATP1A2 |
| Q37918304 | Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy |
| Q50548714 | Excellent outcomes of children with CML treated with imatinib mesylate compared to that in pre-imatinib era. |
| Q91771808 | Factors Influencing Imatinib-Induced Hepatotoxicity |
| Q48174042 | Field-assisted paper spray mass spectrometry for therapeutic drug monitoring: 1. the case of imatinib in plasma |
| Q60021320 | Gastrointestinal Stromal Tumors |
| Q37692669 | Gastrointestinal stromal tumours at present: an approach to burning questions |
| Q46431899 | Gemfibrozil impairs imatinib absorption and inhibits the CYP2C8-mediated formation of its main metabolite. |
| Q42110946 | HSP90 inhibitor AUY922 induces cell death by disruption of the Bcr-Abl, Jak2 and HSP90 signaling network complex in leukemia cells |
| Q37381574 | High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients |
| Q33396265 | High-dose imatinib for newly diagnosed chronic phase chronic myeloid leukemia patients--systematic review and meta-analysis |
| Q54598646 | High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography-Tandem Mass Spectrometry. |
| Q48826707 | How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations. |
| Q36243653 | Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation |
| Q34384711 | Imaging the intracellular distribution of tyrosine kinase inhibitors in living cells with quantitative hyperspectral stimulated Raman scattering |
| Q34022596 | Imatinib 800 mg daily induces deeper molecular responses than imatinib 400 mg daily: results of SWOG S0325, an intergroup randomized PHASE II trial in newly diagnosed chronic phase chronic myeloid leukaemia |
| Q52641813 | Imatinib Affects the Expression of SLC22A1 in a Non-Linear Concentration-Dependent Manner Within 24 Hours. |
| Q48152547 | Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients |
| Q42143116 | Imatinib activates pathological hypertrophy by altering myocyte calcium regulation |
| Q37675128 | Imatinib activity on Schistosoma mansoni |
| Q37571446 | Imatinib and beyond--exploring the full potential of targeted therapy for CML. |
| Q34433289 | Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human plasma |
| Q43076606 | Imatinib dose escalation in two patients with chronic myeloid leukemia, with low trough imatinib plasma levels measured at various intervals from the beginning of therapy and with suboptimal treatment response, leads to the achievement of higher pla |
| Q26865086 | Imatinib in chronic myeloid leukemia: an overview |
| Q38725366 | Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes. |
| Q42258804 | Imatinib mesylate inhibits STAT5 phosphorylation in response to IL-7 and promotes T cell lymphopenia in chronic myelogenous leukemia patients |
| Q43288117 | Imatinib mesylate pharmacokinetics before and after sleeve gastrectomy in a morbidly obese patient with chronic myeloid leukemia. |
| Q42843116 | Imatinib plasma levels: correlation with clinical benefit in GIST patients |
| Q42556614 | Imatinib plasma monitoring-guided dose modification for managing imatinib-related toxicities in gastrointestinal stromal tumor patients |
| Q33557847 | Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients |
| Q83224779 | Imatinib plasma trough levels in chronic myeloid leukaemia: results of a multicentre study CSTI571AIL11TGLIVEC |
| Q28539623 | Imatinib treatment causes substantial transcriptional changes in adult Schistosoma mansoni in vitro exhibiting pleiotropic effects |
| Q88648647 | Imatinib-induced ophthalmological side-effects in GIST patients are associated with the variations of EGFR, SLC22A1, SLC22A5 and ABCB1 |
| Q40751644 | Impact of CYP2C8*3 polymorphism on in vitro metabolism of imatinib to N-desmethyl imatinib |
| Q40876078 | Impact of body surface area on survival in EGFR-mutant non-small cell lung cancer patients treated with gefitinib monotherapy: observational study of the Okayama Lung Cancer Study Group 0703. |
| Q89819938 | Implementation of a Physiologically Based Pharmacokinetic Modeling Approach to Guide Optimal Dosing Regimens for Imatinib and Potential Drug Interactions in Paediatrics |
| Q48189225 | Inadequate response to imatinib treatment in chronic myeloid leukemia due to a drug interaction with phenytoin. |
| Q42933358 | Influence of CYP3A5 and drug transporter polymorphisms on imatinib trough concentration and clinical response among patients with chronic phase chronic myeloid leukemia |
| Q50261890 | Influence of CYP3A5*3 and ABCB1 C3435T on clinical outcomes and trough plasma concentrations of imatinib in Nigerians with chronic myeloid leukaemia. |
| Q42723108 | Influence of H2-receptor antagonists and proton pump inhibitors on dasatinib pharmacokinetics in Japanese leukemia patients |
| Q41612371 | Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib. |
| Q28306900 | Inhibitory effects of imatinib mesylate on human epidermal melanocytes |
| Q37683539 | Integrating pharmacogenetics and therapeutic drug monitoring: optimal dosing of imatinib as a case-example. |
| Q38150978 | Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib. |
| Q51069180 | Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. |
| Q28481327 | Intracellular retention of ABL kinase inhibitors determines commitment to apoptosis in CML cells |
| Q39653324 | KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro |
| Q38937228 | Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure. |
| Q46098047 | Long-term efficacy of imatinib in a practical setting is correlated with imatinib trough concentration that is influenced by body size: a report by the Nagasaki CML Study Group |
| Q54527295 | Long-term outcome following imatinib therapy for chronic myelogenous leukemia, with assessment of dosage and blood levels: the JALSG CML202 study. |
| Q35073857 | Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib |
| Q39141643 | Longitudinal assessment of imatinib's effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI. |
| Q33595519 | Low body weight and body mass index may be associated with musculoskeletal pain following imatinib discontinuation in chronic myeloid leukemia |
| Q27320733 | Low doses of imatinib induce myelopoiesis and enhance host anti-microbial immunity |
| Q94076945 | MDR1和CYP3A5基因多态性对伊马替尼治疗慢性骨髓性白血病预后的影响 |
| Q26766299 | Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment |
| Q37791429 | Management of adverse events associated with tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia |
| Q38101471 | Management options for refractory chronic myeloid leukemia: considerations for the elderly |
| Q84891677 | Measurement of imatinib uptake by flow cytometry |
| Q37896015 | Measuring response to BCR-ABL inhibitors in chronic myeloid leukemia |
| Q34417423 | Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry |
| Q27343176 | MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells |
| Q36779136 | Model-based treatment optimization of a novel VEGFR inhibitor |
| Q47117554 | Molecular Response to Imatinib and Its Correlation with mRNA Expression Levels of Imatinib Influx Transporter (OCT1) in Indian Chronic Myeloid Leukemia Patients |
| Q46534692 | Molecular and cytogenetic response of chronic myelogenous leukemia treated with imatinib mesylate: one institutional experience in Japan. |
| Q53178315 | Molecular diagnostics in chronic myeloid leukemia. |
| Q33750753 | Molecular measurement of BCR-ABL transcript variations in chronic myeloid leukemia patients in cytogenetic remission |
| Q38208748 | Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies |
| Q36184500 | Molecular response to imatinib & its correlation with mRNA expression levels of imatinib influx & efflux transporters in patients with chronic myeloid leukaemia in chronic phase |
| Q36153597 | Monitoring imatinib plasma concentrations in chronic myeloid leukemia |
| Q34761663 | Monitoring response and resistance to treatment in chronic myeloid leukemia |
| Q42380473 | Multifaceted actions of 8-amino-adenosine kill BCR-ABL positive cells |
| Q34522789 | NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemia |
| Q37831034 | Navigating the road toward optimal initial therapy for chronic myeloid leukemia |
| Q33383640 | New approved dasatinib regimen available for clinical use. |
| Q44780863 | Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells |
| Q44027139 | No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia |
| Q36851400 | Normal ABL1 is a tumor suppressor and therapeutic target in human and mouse leukemias expressing oncogenic ABL1 kinases |
| Q40213114 | Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses |
| Q47847397 | Optimizing the dose in cancer patients treated with imatinib, sunitinib and pazopanib |
| Q92188958 | Optimizing the dose in patients treated with imatinib as first line treatment for gastrointestinal stromal tumours: A cost-effectiveness study |
| Q37888714 | Optimizing the selection of kinase inhibitors for chronic myeloid leukemia patients |
| Q37684920 | Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase |
| Q55066758 | Persistent major molecular response to nilotinib therapy in a patient with chronic myeloid leukemia harboring ABL gene T315I mutation. |
| Q26766292 | Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics |
| Q38996487 | Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients |
| Q37353853 | Pharmacokinetic considerations for new targeted therapies. |
| Q39531941 | Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia |
| Q47969048 | Pharmacokinetic-Guided Dosing of New Oral Cancer Agents |
| Q37464749 | Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia |
| Q50279978 | Pharmacokinetics and pharmacodynamics of dasatinib in the chronic phase of newly diagnosed chronic myeloid leukemia. |
| Q44982199 | Pharmacokinetics of single-agent axitinib across multiple solid tumor types. |
| Q36694926 | Phase I clinical trial combining imatinib mesylate and IL-2 in refractory cancer patients: IL-2 interferes with the pharmacokinetics of imatinib mesylate |
| Q51329014 | Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer. |
| Q33574578 | Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). |
| Q37549881 | Phase II trial of imatinib in AIDS-associated Kaposi's sarcoma: AIDS Malignancy Consortium Protocol 042. |
| Q88913397 | Plasma concentrations of dasatinib have a clinical impact on the frequency of dasatinib dose reduction and interruption in chronic myeloid leukemia: an analysis of the DARIA 01 study |
| Q35930616 | Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial |
| Q103002088 | Plasma imatinib levels and ABCB1 polymorphism influences early molecular response and failure-free survival in newly diagnosed chronic phase CML patients |
| Q48217300 | Plasma vemurafenib concentrations in advanced BRAFV600mut melanoma patients: impact on tumour response and tolerance |
| Q39816193 | Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib |
| Q41404164 | Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase |
| Q51088241 | Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia. |
| Q39429946 | Practical Recommendations for Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology |
| Q38190857 | Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: focus on the pharmacokinetic targets |
| Q37738567 | Predicting the response of CML patients to tyrosine kinase inhibitor therapy |
| Q37859303 | Predicting the response of CML patients to tyrosine kinase inhibitor therapy |
| Q36729934 | Prediction of free imatinib concentrations based on total plasma concentrations in patients with gastrointestinal stromal tumours |
| Q46131305 | Prediction of response to imatinib in patients with chronic myelogenous leukemia by flow cytometric analysis of bone marrow blastic cell phenotypes |
| Q34443523 | Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase |
| Q38095956 | Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and Monitoring |
| Q37650706 | Prospective Analysis in GIST Patients on the Role of Alpha-1 Acid Glycoprotein in Imatinib Exposure |
| Q96306846 | Quantification of imatinib and related compounds using capillary electrophoresis-tandem mass spectrometry with field-amplified sample stacking |
| Q37085189 | Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays. |
| Q61804715 | Randomized study of imatinib for chronic myeloid leukemia: comparing standard dose escalation with aggressive escalation |
| Q46035698 | Relationship between an effective dose of imatinib, body surface area, and trough drug levels in patients with chronic myeloid leukemia. |
| Q36667469 | Relationship of imatinib-free plasma levels and target genotype with efficacy and tolerability |
| Q88961723 | Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma |
| Q27028181 | Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options |
| Q37810111 | Role of gene-expression profiling in chronic myeloid leukemia |
| Q34525644 | SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia |
| Q30891587 | Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. |
| Q37811878 | Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia |
| Q34705820 | Serum albumin and α-1 acid glycoprotein impede the killing of Schistosoma mansoni by the tyrosine kinase inhibitor Imatinib |
| Q36407123 | Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor. |
| Q28292463 | Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib |
| Q37148391 | Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy? |
| Q37810110 | Suboptimal responses in chronic myeloid leukemia: milestones and mechanisms |
| Q33396613 | Sunitinib for Asian patients with advanced renal cell carcinoma: a comparable efficacy with different toxicity profiles. |
| Q47877771 | Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia |
| Q37509428 | TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets |
| Q37710963 | Targeted cancer therapies in the twenty-first century: lessons from imatinib |
| Q37810070 | Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug design in cancer |
| Q90478736 | The Steps to Therapeutic Drug Monitoring: A Structured Approach Illustrated With Imatinib |
| Q35221071 | The choice of first-line chronic myelogenous leukemia treatment |
| Q50784710 | The clinical significance of ABCB1 overexpression in predicting outcome of CML patients undergoing first-line imatinib treatment. |
| Q37814411 | The expanding role of nilotinib in chronic myeloid leukemia |
| Q34469295 | The pharmacogenetics of imanitib |
| Q33725976 | The quest to overcome resistance to EGFR-targeted therapies in cancer |
| Q37694432 | The role of high-dose imatinib in the management of patients with gastrointestinal stromal tumor |
| Q37817815 | The role of imatinib plasma level testing in gastrointestinal stromal tumor |
| Q41846251 | Therapeutic drug monitoring and tyrosine kinase inhibitors |
| Q37517632 | Therapeutic drug monitoring for imatinib: Current status and Indian experience |
| Q37810220 | Therapeutic drug monitoring in cancer chemotherapy |
| Q37862942 | Therapeutic drug monitoring of imatinib for chronic myeloid leukemia patients in the chronic phase |
| Q46573433 | Therapeutic drug monitoring of imatinib in chronic myeloid leukemia: experience from 1216 patients at a centralized laboratory. |
| Q39651800 | Therapeutic drug monitoring of imatinib: Bayesian and alternative methods to predict trough levels. |
| Q38579278 | Therapeutic drug monitoring of targeted anticancer therapy |
| Q58023832 | Therapy of Newly Diagnosed and Chronic-Phase Chronic Myeloid Leukemia |
| Q41900650 | Threshold levels of ABL tyrosine kinase inhibitors retained in chronic myeloid leukemia cells determine their commitment to apoptosis |
| Q46218126 | Translational research in complex etiopathogenesis and therapy of hematological malignancies: the specific role of tyrosine kinases signaling and inhibition |
| Q39125281 | Treating Philadelphia chromosome/BCR-ABL1 positive patients with Glivec (Imatinib mesylate): 10 years' experience at Patan Hospital, Nepal |
| Q43932267 | Treatment of advanced gastrointestinal stromal tumors in patients over 75 years old: clinical and pharmacological implications. |
| Q37827875 | Treatment of chronic myeloid leukemia when imatinib fails |
| Q38797683 | Treatment of chronic myeloid leukemia: assessing risk, monitoring response, and optimizing outcome. |
| Q51251518 | Trough concentration and ABCG2 polymorphism are better to predict imatinib response in chronic myeloid leukemia: a meta-analysis. |
| Q33394772 | Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia. |
| Q30242015 | Tyrosine kinase inhibitors in chronic myeloid leukaemia: which, when, for whom? |
| Q58752788 | Ultrasound assisted dispersive micro solid-phase extraction of four tyrosine kinase inhibitors from serum and cerebrospinal fluid by using magnetic nanoparticles coated with nickel-doped silica as an adsorbent |
| Q33644791 | Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib. |
| Q54630282 | Who is in charge of assessing therapeutic drug monitoring? The case of imatinib. |
| Q89550090 | [Comparison of nilotinib vs imatinib as frontline therapy in newly diagnosed patients with chronic myeloid leukemia in chronic phase] |
| Q55069281 | [Metastasized renal cell carcinoma. Measurement of plasma levels of the tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib]. |
Search more.